6-Ethyl-2-azaspiro[3.3]heptane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 6-Ethyl-2-azaspiro[3.3]heptane
• 英文别名: 6-ethyl-2-azaspiro[3.3]heptane
• 化学式: C₈H₁₅N
• 分子量: 125.21
• InChiKey: VCKJDFXJUBGCIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：GENENTECH INC

  公开号：WO2016123387A1

  公开（公告）日：2016-08-04

  Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.

  本文提供了公式I的化合物及其盐、组合物和用途。这些化合物可用作LSD1的抑制剂。还包括含有公式I化合物或其药用盐的药物组合物，以及在治疗各种LSD1介导的疾病中使用这些化合物和盐的方法。
• [EN] 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS DE 2-PYRIDAZIN-3(2H)-ONE À SUBSTITUTION 2-ARYLE ET 2-HÉTÉROARYLE UTILISÉS EN TANT QU'INHIBITEURS DE FGFR TYROSINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017070708A1

  公开（公告）日：2017-04-27

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

  本文提供了一般式I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中X、R1、R2、R3、环A和z的含义如规范中所述，这些化合物是FGFR1、FGFR2、FGFR3和/或FGFR4的抑制剂，可用于治疗和预防可以用FGFR抑制剂治疗的疾病，包括由FGFR1、FGFR2、FGFR3和/或FGFR4介导的疾病或障碍。
• [EN] CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS<br/>[FR] INHIBITEURS DE CDK ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：PRELUDE THERAPEUTICS INC

  公开号：WO2022133215A1

  公开（公告）日：2022-06-23

  The disclosure is directed to compounds of Formula (I), pharmaceutical compositions comprising compounds of Formula (I), as well as methods of their use and preparation, are also described.

  本公开说明涉及公式（I）的化合物，包括含有公式（I）化合物的制药组合物，以及它们的使用和制备方法。
• [EN] UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE LA PROTÉASE 7 DE TRAITEMENT SPÉCIFIQUE DE L'UBIQUITINE (USP7) ET LEURS UTILISATIONS
  申请人：RAPT THERAPEUTICS INC

  公开号：WO2020068600A1

  公开（公告）日：2020-04-02

  Disclosed herein are, inter alia, compounds of formula (I) and methods of use thereof for the modulation of USP7 activity and for use in treating cancer.